OPEN ACCESS Freely available online

Pharmaceutical Analytical Chemistry: Open Access

Perspective

Analytical Control Strategies in the Manufacture of Modified-Release Dosage Forms

Alexander Fischer*

Department of Pharmaceutical Analysis, University of Oxford, Oxford, UK

DESCRIPTION

Modified-Release (MR) dosage forms offer therapeutic advantages by controlling the rate, timing, and location of drug release. However, their complexity necessitates robust analytical control strategies to ensure product quality, safety, and efficacy throughout the manufacturing process. This article presents a perspective on the development and implementation of analytical control strategies specific to MR formulations, with an emphasis on critical quality attributes, regulatory expectations, and lifecycle management.

Modified-release dosage forms are designed to deliver drugs at predetermined rates over extended periods or to targeted regions within the gastrointestinal tract. These systems include Extended-Release (ER), Delayed-Release (DR), pulsatile, and gastro retentive formulations. While offering benefits such as improved patient compliance and optimized therapeutic outcomes, MR products present significant analytical and manufacturing challenges. Their performance depends on multiple factors, including formulation composition, release-controlling mechanisms, and process parameters. Therefore, robust and well-defined analytical control strategies are essential to monitor these variables and ensure consistent product performance.

In pharmaceutical manufacturing, analytical control strategies refer to the set of analytical methods, specifications, and acceptance criteria applied across the product lifecycle from raw material testing to in-process controls and final product release. For MR formulations, control strategies must be particularly stringent due to their complexity and susceptibility to variability.

Each CQA must be matched with an appropriate analytical technique. For example, High-Performance Liquid Chromatography (HPLC) is used for potency and content uniformity, while dissolution testing evaluates release kinetics. Advanced imaging techniques like Near-Infrared Spectroscopy (NIR) and Raman microscopy can assess coating uniformity and thickness in real time. Dissolution testing holds special importance in MR dosage forms, as it directly correlates with drug release behavior. Analytical strategies must include method development and validation of discriminatory dissolution tests that can differentiate between formulation changes or process deviations. Multiple dissolution media, pH conditions, and agitation speeds may be used to simulate gastrointestinal environments. Additionally, *In Vitro-In Vivo* Correlation (IVIVC) studies can be employed to strengthen the clinical relevance of dissolution profiles and justify bio-waivers in certain cases.

In-process analytical controls are important for maintaining the quality of MR dosage forms during manufacturing. The adoption of Process Analytical Technology (PAT) tools enhances these in-process controls. PAT enables Real-Time Release Testing (RTRT), allowing manufacturers to make immediate adjustments and minimize deviations. Coating plays a central role in MR formulations, especially in enteric and extended-release systems. Variability in coating application can drastically affect drug release rates.

Regulatory agencies expect comprehensive analytical control strategies to be integrated into the product's overall control framework. Guidelines such as ICH Q8-Q10 emphasize a Quality-by-Design (QbD) approach that includes defining a design space, implementing control strategies, and adopting a lifecycle management plan.

Dissolution specifications, acceptance criteria for CQAs, and validated analytical methods must be thoroughly documented. Additionally, changes in manufacturing scale, site, or equipment may require method revalidation or bridging studies to maintain regulatory compliance.

An effective control strategy is not static. It must evolve based on process understanding, post-market surveillance, and technological advancements. Method lifecycle management (MLCM) involves continuous monitoring, trending of analytical data, and periodic method requalification. This approach ensures long-term method suitability and supports continuous improvement. The manufacturing of modified-release dosage forms demands comprehensive analytical control strategies tailored to their unique challenges. From dissolution testing to coating assessments and real-time monitoring, each element of the strategy must be aligned with the goal of delivering a safe, effective, and consistent product. As regulatory expectations and analytical technologies evolve, so too must the control frameworks that support modern pharmaceutical manufacturing.

Correspondence to: Alexander Fischer, Department of Pharmaceutical Analysis, University of Oxford, Oxford, UK, E-mail: emily.greenfield@chem.ox.ac.uk

Received: 13-Feb-2025, Manuscript No. PACO-25-38205; **Editor assigned:** 17-Feb-2025, PreQC No. PACO-25-38205 (PQ); **Reviewed:** 03-Mar-2025, QC No. PACO-25-38205; **Revised:** 10-Mar-2025, Manuscript No. PACO-25-38205 (R); **Published:** 17-Mar-2025, DOI: 10.35248/2471-2698.10.286

Citation: Fischer A (2025) Analytical Control Strategies in the Manufacture of Modified-Release Dosage Forms. Pharm Anal Chem. 10:286.